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Summary.-Biopsy specimens from nasopharyngeal carcinomas (NPC) or salivary-
gland carcinomas (SGC) in Greenland Eskimoes were examined for the presence of
Epstein-Barr virus (EBV) DNA and sera from the patients were tested for EBV-
specific antibody titres. Six out of 7 NPCs and one from an undifferentiated SGC
were positive for EBV DNA. The EBV-specific antibody spectra and titres of the
patients with NPC or undifferentiated SGC conformed to the results of earlier
studies in other high-incidence areas.
THE EPSTEIN-BARR VIRUS (EBV) was
originally detected in cultured African
Burkitt's lymphoma (BL) cells in 1964
(Epstein et al., 1964, 1965). Two years
later tests for EBV-specific precipitating
antibodies suggested an association of the
virus with nasopharyngeal carcinoma
(NPC) in East African and American
patients (Old et al., 1966). It was rapidly
shown thereafter that NPC patients had
elevated titres of IgG antibodies to EBV
viral capsid antigen (VCA) and to the
diffuse (D) component ofthe early-antigen
(EA) complex (Henle et al., 1970, 1971,
1977). IgA antibodies to these 2 antigens
were also often demonstrable in sera from
NPC patients (Henle & Henle, 1976;
Henle et al., 1977). This pattern ofelevated
IgG and IgA antibodies to VCA and EA
(D) has been found uniformly in NPC
patients, whether from low- or high-risk
areas (Henle & Henle, 1976; Henle et al.,
1977; de The et al., 1978; Klein, 1979;
Lanier et al., 1981). The association of
NPC with EBV has been further strength-
ened by the detection of EBV genomes in
the malignant epithelial cells by nucleic-
acid hybridization techniques (zur Hausen
et al., 1970, 1974; Nonoyama et al., 1973;
Wolf et al., 1973, 1975) and by demon-
stration of EBV nuclear antigen (EBNA)
in the carcinoma cells (Huang et al.,
1974; Klein et al., 1974). Recently Ander-
son-Anvret et al. (1977, 1978, 1979) have
shown that the regular association of
EBV with NPC holds good for the
undifferentiated or non-keratinizing type
(WHO-2 and WHO-3 classification) which
dominate in high-risk areas (Clifford &
Beecher, 1964; Schmauz & Templeton,
1972; Nielsen et al., 1977), but not for
well-differentiated tumours (WHO-1).
Sero - epidemiological studies have
demonstrated a worldwide distribution of
EBV, more than 90% of all adults being
seropositive (llcile & Henle, 1979a). The
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incidence of the associated malignancies
(BL and NPC) varies considerably, how-
ever, with ethnic background and geo-
graphic location. The incidence of NPC
is very high in South-east China, East
Africa and among Alaskan, Canadian and
Greenlandic Eskimoes as compared to the
rest of the world (Schafer et al., 1975;
Lanier et al., 1976; Nielsen et al., 1977;
de The, 1979).
In Greenland, which has more than
40,000 inhabitants of Eskimo ancestry,
the incidence of NPC per 100,000 has
recently been found to be 12 3 for males
and 8-5 for females (Nielsen et al., 1977).
Thus the frequency of NPC in Greenland
is among the highest on record. Another
cancer, salivary-gland carcinoma (SGC),
has a high incidence among Greenlandic
Eskimoes: 3 9 for males and 77 for
females. More than 90°/% of these tumours
are located in the parotid gland and at the
histopathological level they appear to be
indistinguishable from undifferentiated
NPC (Nielsen et al., 1978). It was thus of
interest to examine not only the associa-
tion of EBV with NPC, but also with
SGC in Greenland. The populationi struc-
ture and medical facilities in Greenland
have been described previously (Nielsen
et al., 1977).
MATERIALS AND) METHODS
From December 1977 to August 1981, 16
Greenlanders suffering from NPC or SGC
wNere sent for treatment to Copenhagen. One
patient refused biopsy and treatment despite
clinically evident NPC, and 2 others with
SGC had their tumours extirpated in Green-
land. These 3 patients are not included in the
present report. Ten of the remaining 13
patients had NPC and 3 had SGC. Six wrere
males and 7 females. Median age was 49 years
(range 30-74). All patients were staged
according to UICC recommendations (1979).
All had X-ray examinations of the chest.
post-nasal space and base of the skull. Serum
levels of aspartate aminotransferase and
alkaline phosphatase were determined in ali
cases.
TwNo biopsY, samples w\ere taken fromn
adjacent sites of the tumour in the naso-
pharynx or salivary gland. One biopsy was
prepared for histopathological examination
and the other for nucleic-acid hybridization.
Tissue for histopathological examination was
immediately fixed in buffered neutral 1000
formalin. The specimens were embedded in
paraffin and sections w-ere routinely stained
with haematoxylin-eosin and by van Geison-
Hansen's method. Supplementary stains were
employed wrhen necessary. Tissue for nucleic-
acid hybridization was immediately frozen
and sent in dry ice by air to Stockholm, where
it was received on thle same day. Sera wxere
taken on the day of operation and sent in the
same container to Stockholm for trans-ship-
ment to Philadelphia, U.S.A. IgA and IgG
serum antibodies to VCA and to the D and
restricted (R) components of the early-
antigen complex were determined by indirect
immunofluorescence (Henle et al., 1974:
Henle & Henle, 1976). Antibodies to R can-
not be measured in the presence ofD immuno-
fluorescence unless thev exceed in titre the
anti-D level (Henle et al., 1971). Antibody
titres to EBNA were determined by anti-C'
immunofluorescence as previously described
(Reedman & Klein. 1973).
EBV DNA for nucleic-acid lhybridization
was prepared as described by Adams (1975) ot
provided by Dr Meihan Nonoyama, Life
Sciences, Inc., St Petersburg, Florida (under
a contract from the Division of Cancer
Cause and Prevention, National Cancer
Institute, U.S. Public Health Service). 32p_
labelled EBV complementary RNA (cRNA)
was prepared according to the method of
Lindahl et al. (1976) and 32P-labelled virus
DNA (vDNA) by nick-translation as previ-
ously described (Rymo, 1979). The isolation
of cellular DNA (Petterson & Sambrook.
1973) and the use of cRNA-DNA filter
hybridization and vDNA-DNA reassociation
kinetic analysis, for the determination of the
number of EBV genome equivalents, has
been described in detail elsew%here (Lindahl
et al., 1976; Anderson-Anvret et al.. 1977:
Saemundsen et al., 1981).
RESULTS
Nasopharyngeal carcinoma
All 10 patients were clinically in Stage
IV. Two had distant metastases when
admitted. Histopathological examination
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FIG. 1.-Histopathological section ofundifferentiated carcinoma of the nasopharynx. Haematoxylin-
eosin stain. (a) x 140, (b) x 350.
demonstrated undifferentiated carcinomas
in all 10 patients (Figs la, b). In 6/10
cases nucleic - acid hybridization with
cRNA revealed 2-50 EBV genome equiva-
lents per cell (Table I). In one case (K.G.)
retested by vDNA reassociation kinetic
analysis, 9 genome equivalents were
detected (Fig. 2). In 3 cases the hybridiza-
tion could not be performed due to
technical failures and 1 other case gave a
negative result. In this last case the
specimen used for histopathology con-
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TABLE I.-EBV antibody titres and genome equivalents in tumour tissuefrom Greenlandic
NPC cases
Serum titres
VCA EA-D Genome
I equivalents
Patienit Sex Age Histopathology IgA IgG IgA IgG EBNA cRNA-DNA
S.S. F 55 Undifferentiated 160 1280 160 640 160 23
H.H. F 53 Undifferentiated 160 1280 40 160 320 23
S.M. M 53 Undifferentiated 40 2560 ND 160 320 50
K.G. M 37 Undifferentiated 40 640 < 10 160 320 2
P.M. M 30 Undifferentiated 160 640 20 40 80 14
A.B. F 66 Undifferentiated 320 1280 ND 160 80 2
G.S.a M 49 Undifferentiated 80 1280 < 10 <10 80 <1
B.M.a F 47 Undifferentiated <10 640 < 10 < 10 80 ND
K.N.b M 45 Undifferentiated 80 640 10 80 160 ND
T.K.b F 44 Undifferentiated < 10 1280 <10 10 320 ND
a Parallel biopsy sample contained no tumour tissue.
b Specimen thawed during transport.
ND=not done.
1.4
n
-
11
1.2.
TIME (H)
FIG. 2. Reassociation kinetic analysis on
DNA from one case of NPC (K.G.). All
samples contained 200 ,ug/ml of cellular
DNA and 1 ng of 32P-EBV DNA. By
comparing the slopes of the positive
control (Raji; 50 genomes/cell) and the
negative control (calf-thymus DNA) to
that of the unknown sample, the tumour
of K.G. was determined to contain 9 EBV
genome equivalents per cell.
tained no tumour tissue (Table I). EBV-
specific antibody patterns were compar-
able to those seen in NPC patients from
other high-incidence areas (Henle et al.,
1971; Henle & Henle, 1976; de The et al.,
1978; Klein, 1979; Lanier et al., 1981).
The titres ranged for IgG anti-VCA from
640 to 2560, IgA anti-VCA from < 10 to
320, IgG anti-D from < 10 to 640, IgA
anti-D from < 10 to 160 and anti-EBNA
from 80 to 320 (Table I).
Salivary gland carcinomas
Of the 3 patients studied, 2 had an
operable and 1 an inoperable tumour of
the parotid gland. In 2 cases the histo-
pathological appearance was compatible
with that of typical undifferentiated
NPC (Figs. 3a, b). The third tumour was a
poorly differentiated adenocarcinoma. In
every case a biopsy sample of the naso-
pharyngeal mucosa on the same side as the
parotid tumour, obtained as control,
contained no tumour tissue.
Nucleic-acid hybridization was per-
formed on the adenocarcinoma and one
ofthe undifferentiated carcinomas. cRNA-
DNA filter hybridization (Table II) and
vDNA reassociation kinetic analysis (Fig.
4) demonstrated a significant number of
EBV genome equivalents in the un-
differentiated carcinoma. No EBV gen-
omes could be detected in the adeno-
carcinoma. (Table II; Fig. 4).
Sera from the patients with undifferen-
tiated carcinomas showed patterns of
EBV-specific antibodies within the range
seen in NPC patients. In the patient with
the adenocarcinoma, onlyVCA and EBNA
antibodies were detected (Table II).
DISCUSSION
The EBV-related serology and the
search for EBV genomes or EBNA-
positive carcinoma cells have become
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FIG. 3. Histopathological section of undifferentiated salivary gland carcinoma. Haematoxylin-
eosin stain. (a) x 140, (b) x 350.
useful diagnostic tools in NPC. Our
findings of a significant number of EBV
genome equivalents in NPC patients from
Greenland are in accord with earlier
reports on undifferentiated NPC in China
and Africa and the more recent reports
of Lanier et al. (1980, 1981) on NPC in
Alaskan natives, most of them being
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TABLE II. EBV antibody titres and qenoone equivalents in tumitour tissuefrom Greenlandic
SGC cases
Histopat hology
Undifferentiated
Undifferentiated
A(lenoeareinoma,
VCIA
IgA 1p
1l6() *}'
10
40
Serum titres
EA - F)
G IgA, IgG
56() 10 1 280
64() 10 20
320 < 10 < 10
TIME (H)
1XIGCX. 4.- Reassociationl kinetic anal.ysis on
D)NA from a ease Of u1ndifferentiatedI SGCR
(J.J.) an(l a(JenoIarcinoma (L.A.). All
Saml)leS COntaine(l 100 Jg/ml cellular DNA
andl ng Of 32P-E13V I)NAR. J.J. w\as
(letermine(l to contain 17 EBV genome
equivalents (&eli whTile L.A. as
learly negative.
Eskimoes. Furthermore, the serological
profiles covered the same range as found
elsewhere in patients from high-risk areas
(Henle et al., 1970, 1971, 1977; Henle &
Henle, 1976; de The et al., 1978; Lanier
et al., 1981).
Another type of malignancy more
common in Eskimoes, as compared to
other ethnic groups, is cancer of the
salivary glands (Schafer et al., 1975;
Nielsen et al., 1978). Over a 20-year
period 920 of malignant salivary-gland
neoplasms in Greenland were identified
as undifferentiated carcinomas (Nielsen
et al., 1978). Of the 3 cases of salivary
gland carcinomas presented here, 2 had
undifferentiated carcinomas and 1 a poorly
differentiated adenocarcinoma EBV-
specific sertum antibodY titres indicated
an enhanced antigenic stimulation in all
3 cases. That in itself was not surprising
since it has long been known that many
malignant and non-malignant diseases
cause an increase in EBV-specific anti-
body titres, presumably due to activation
of the persistent viral carrier state, which
reguarly follows primary infection with
EBV (Henle & Henle, 1979a). An import-
ant finding, however, was the detection of
a significant number of EBV genome
equivalents in 1 of the 2 biopsy specimens
examined, both by eRNA filter hybridiza-
tion and by vDNA reassociation kinetic
analysis. This biopsy specimen, from a
parotid gland tumour, contained an un-
differentiated carcinoma. This observa-
tion corroborates the findings of Lanier
et al. (1981) of significant numbers of
EBV genome equivalents in 2 salivary
gland tumours of Alaskan Eskimoes. It
has long been suspected that the primary
site of infection with EBV' is somewhere
in the oropharynx, and that EBV may
replicate in normal salivary glands, especi-
ally the parotid gland (Niederman et al.,
1976; Morgan et al., 1979). Furthermore,
the parotid gland has been implicated as a
possible habitat ofEBV by demonstration
of EBV genomes in normal gland tissue
by in situ hybridization and reassociation
kinetic analysis (Wolf et al., 1981). Thus
the question remains unanswered whether
EBV is present merely as a passenger
derived from one of its natural sites of
persistence, or causally related to un-
differentiated salivary-gland carcinoma.
In some cases ofsalivary-gland carcinoma,
a secondary NPC cannot be excluded
IL'at .iit
.r.J.
L..A.
Sex
F
Age
74
5()
44
a Biopsy (lone in (GIreeniland.
N 1) = not (loIne.
E13-NA
16(
20
40)
Geniome
equivalents
(RNA\-NA
NI)
26
<1I
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(Nielsen et al., 1978; Lanier et al., 1981)
but, in the 3 cases described here, biopsy
samples from the nasopharynx contained
no tumour tissue.
EBV is the causative agent ofinfectious
mononucleosis (Henle & Henle, 1979b) and
is uniquely associated with BL (Epstein
& Achong, 1979) and NPC (Anderson-
Anvret et al., 1978; Klein, 1979). Recently,
a link has also been demonstrated between
EBV and certain lymphoproliferative dis-
orders that occurinpatients with inherited
oracquired immunodeficiencies (Saemund-
sen et al., 1981). In BL and NPC "associa-
tion" refers to the regular presence of
EBV genomes and the consequent expres-
sion of EBNA in all tumour cells. The
regular association of a virus with a
given tumour, irrespective of geographic
differences in its distribution, affords
strong evidence for a causal relationship
of that virus to that particular cancer.
The results presented here thus lend
further support to an aetiological role for
EBV in NPC. It is clear, however, that
because of the unusual geographic and
ethnic distribution of NPC, both genetic
and environmental factors contribute to
the aetiology of this tumour (Anderson-
Anvret et al., 1978; Klein, 1979).
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